Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC

被引：6

作者：

Evans, Rachel ^{[1
]}

Lee, Kelvin ^{[2
]}

Wallace, Paul K. ^{[1
]}

Reid, Mary ^{[1
]}

Muhitch, Jason ^{[1
]}

Dozier, Askia ^{[1
]}

Mesa, Circe ^{[3
]}

Luaces, Patricia L. ^{[3
]}

Santos-Morales, Orestes ^{[3
]}

Groman, Adrienne ^{[1
]}

Cedeno, Carlos ^{[1
]}

Cinquino, Aileen ^{[1
]}

Fisher, Daniel T. ^{[1
]}

Puzanov, Igor ^{[1
]}

Opyrchal, Mateusz ^{[2
]}

Fountzilas, Christos ^{[1
]}

Dai, Tong ^{[1
]}

Ernstoff, Marc ^{[4
]}

Attwood, Kristopher ^{[1
]}

Hutson, Alan ^{[1
]}

Johnson, Candace ^{[1
]}

Mazorra, Zaima ^{[3
]}

Saavedra, Danay ^{[3
]}

Leon, Kalet ^{[3
]}

Lage, Agustin ^{[3
]}

Crombet, Tania ^{[3
]}

Dy, Grace K. ^{[1
]}

机构：

[1] Roswell Pk Comprehens Canc Ctr, Buffalo, NY 14203 USA

[2] Indiana Univ, Dept Med, Melvin & Bren Simon Comprehens Canc Ctr, Indianapolis, IN USA

[3] Ctr Immunol Mol, Havana, La Habana, Cuba

[4] Natl Canc Inst NCI, Div Canc Treatment & Diag, Bethesda, MD USA

来源：

FRONTIERS IN ONCOLOGY | 2022年 / 12卷

关键词：

immunotherapy; lung cancer; non-small cell lung cancer; immune checkpoint inhibitor; vaccine; LONG-TERM SURVIVAL; LUNG-CANCER; CHECKMATE; 017; VACCINE; DOCETAXEL; OUTCOMES; THERAPY; BURDEN; PD-1;

D O I：

10.3389/fonc.2022.958043

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundCIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shown survival benefit as a switch maintenance treatment after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). The primary objective of this trial is to establish the safety and recommended phase II dose (RP2D) of CIMAvax-EGF in combination with nivolumab as second-line therapy for NSCLC. MethodsPatients with immune checkpoint inhibitor-naive metastatic NSCLC were enrolled using a "3+3" dose-escalation design. Toxicities were graded according to CTCAE V4.03. Thirteen patients (one unevaluable), the majority with PD-L1 0%, were enrolled into two dose levels of CIMAvax-EGF. FindingsThe combination was determined to be safe and tolerable. The recommended phase 2 dose of CIMAvax-EGF was 2.4 mg. Humoral response to CIMAvax-EGF was achieved earlier and in a greater number of patients with the combination compared to historical control. Four out of 12 evaluable patients had an objective response.

引用

页数：11

共 2 条

[1] Interim Results from a Phase I/II Trial of Nivolumab in Combination with CIMAvax-EGF as Second-Line Therapy in Advanced NSCLC
Dy, G.
Dozier, A.
Reid, M.
Lee, K.
Miller, A.
Wallace, P.
Puzanov, I.
Opyrchal, M.
Ernstoff, M.
Johnson, C.
Mazorra, Z.
Saavedra, D.
Leon, K.
Lage, A.
Crombet, T.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S740 - S740
[2] Ongoing Phase II Trial of Anti-PD1 Therapy in Combination with CIMAvax-EGF in Patients with Advanced NSCLC or Squamous Cell Head and Neck Cancer
Dy, G.
Crombet, T.
Leon, K.
Mazzora, Z.
Hernandez, D.
Lage, A.
Dozier, A.
Chen, H.
Hutson, A.
Plessinger, D.
Johnson, C.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S970 - S970

← 1 →